Corvus Pharmaceuticals, Inc. (CRVS) total debt
Corvus Pharmaceuticals, Inc. (CRVS) carried total debt of $937.00K at the end of fiscal 2025 (December 31, 2025). That is 16.5% lower than the $1.12M of fiscal 2024. Figures as of 18 Nov 2026, 09:52 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $937.00K
- Change on fiscal 2024
- −16.5%
- Highest on record
- $2.60Mfiscal 2022
- Lowest on record
- $937.00Kfiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Corvus Pharmaceuticals, Inc. total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $2.60M in fiscal 2022 and the lowest $937.00K in fiscal 2025.
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Corvus Pharmaceuticals, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $937.00K | 16.5% down | 0.0× | |
| 2024 | $1.12M | 18.3% down | 0.0× | |
| 2023 | $1.37M | 47.2% down | 0.0× | |
| 2022 | $2.60M | — | 0.0× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Corvus Pharmaceuticals, Inc., figure by figure
- Corvus Pharmaceuticals, Inc. market cap
- Corvus Pharmaceuticals, Inc. revenue
- Corvus Pharmaceuticals, Inc. earnings
- Corvus Pharmaceuticals, Inc. earnings per share (EPS)
- Corvus Pharmaceuticals, Inc. P/E ratio
- Corvus Pharmaceuticals, Inc. P/S ratio
- Corvus Pharmaceuticals, Inc. P/B ratio
- Corvus Pharmaceuticals, Inc. free cash flow
- Corvus Pharmaceuticals, Inc. operating margin
- Corvus Pharmaceuticals, Inc. dividend
- Corvus Pharmaceuticals, Inc. shares outstanding
- Corvus Pharmaceuticals, Inc. cash on hand
- Corvus Pharmaceuticals, Inc. total assets
- Corvus Pharmaceuticals, Inc. return on equity (ROE)
- Corvus Pharmaceuticals, Inc. return on invested capital (ROIC)
Corvus Pharmaceuticals, Inc. (CRVS) overview: price, valuation and scorecard
Corvus Pharmaceuticals, Inc. total debt: questions and answers
How much debt does Corvus Pharmaceuticals, Inc. have?
Corvus Pharmaceuticals, Inc. (CRVS) carried total debt of $937.00K at the end of fiscal 2025 (December 31, 2025). That is 16.5% lower than the $1.12M of fiscal 2024.
What are the highest and lowest total debt figures on record for Corvus Pharmaceuticals, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $2.60M in fiscal 2022 and the lowest $937.00K in fiscal 2025.
How does Corvus Pharmaceuticals, Inc.'s debt compare with its equity?
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
How is Corvus Pharmaceuticals, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For Corvus Pharmaceuticals, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Corvus Pharmaceuticals, Inc. (CRVS) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/CRVS/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.